Showing results (51-60 of 352) with videos related to
Sort By:
Pageof 36
The New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D ChambersMabs|March 2, 2012
The cost-effectiveness of biopharmaceuticals: a look at the evidenceAndrew W Wilson, Peter J NeumannThe Synthesis Project. Research Synthesis Report|November 5, 2011
Cost savings and cost-effectiveness of clinical preventive carePeter J Neumann, Joshua T CohenHealth Policy (Amsterdam, Netherlands)|October 10, 2009
Personalized medicine: factors influencing reimbursementLisa M Meckley, Peter J NeumannAlzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2012
The economics of mild cognitive impairmentPei-Jung Lin, Peter J NeumannHealth Affairs (Project Hope)|May 9, 2007
What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits)Joshua T Cohen, Peter J NeumannValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
FDA actions against health economic promotions, 2002-2011Peter J Neumann, Sarah K BlissHarefuah|September 1, 2007
[Threshold values for cost-effectiveness ratio and public funding of medical technologies]Mordechai Rabinovich, Dan Greenberg, Joshua ShemerMedical Decision Making : an International Journal of the Society for Medical Decision Making|August 3, 2005
Can we better prioritize resources for cost-utility research?Peter J Neumann, Allison B Rosen, Dan Greenberg, et al.The Oncologist|February 16, 2006
Do oncologists believe new cancer drugs offer good value?Eric Nadler, Ben Eckert, Peter J NeumannPageof 36